BYM338 vs Human Insulin
Head-to-head comparison of BYM338 (Bimagrumab (BYM338)) and Human Insulin (Insulin (recombinant human insulin)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | BYM338 | Human Insulin |
|---|---|---|
| Category | Muscle & Performance | Muscle & Performance |
| Full Name | Bimagrumab (BYM338) | Insulin (recombinant human insulin) |
| Molecular Weight | ~148 kDa | 5808 Da |
| Half-Life | ~2-3 weeks | 5-10 minutes |
| Amino Acids | N/A | 51 |
| Typical Dose | 10-30 mg/kg IV in trials | 0.05-0.3 U/kg |
| Route | Intravenous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 140 | 5000 |
| Research Status | Clinical | Clinical |
BYM338 Benefits
- ✓increased lean mass
- ✓functional strength support
- ✓reduced muscle wasting
- ✓metabolic body-composition shift
Human Insulin Benefits
- ✓reduces proteolysis
- ✓improves nutrient partitioning
- ✓supports glycogen replenishment
- ✓enhances postprandial muscle protein balance
BYM338 Dosing
IV infusion|10-30 mg/kg per study cycle|repeat every 4-12 weeks
Human Insulin Dosing
0.05-0.3 U/kg SC (clinical)|timed with carbohydrate/protein intake|individualized glucose monitoring required
BYM338 Side Effects
- ⚠muscle cramps
- ⚠diarrhea/nausea
- ⚠infusion reactions
Human Insulin Side Effects
- ⚠hypoglycemia
- ⚠weight or fat gain
- ⚠injection-site reactions
Research Overview
BYM338
Clinical trials showed meaningful increases in lean mass, with mixed functional outcomes depending on population and endpoint. The antibody remains one of the best-documented receptor-blocking approaches to muscle anabolism in humans.
Human Insulin
Human and animal studies show insulin powerfully suppresses whole-body and muscle protein breakdown while increasing amino acid uptake and glycogen storage. It is widely established in clinical nutrition and endocrinology, with anabolic effects on muscle being secondary to its anti-catabolic action.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.